Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis by Kay, Jonathan & Rahman, Mahboob U
© 2009 Kay and Rahman, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Core Evidence 2009:4 159–170
Core Evidence
159
R E v i E w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Golimumab:   A novel human anti-TNF-α 
monoclonal antibody for the treatment  
of rheumatoid arthritis, ankylosing spondylitis,  
and psoriatic arthritis
Jonathan Kay1 
Mahboob U Rahman2,3
1Division of Rheumatology, UMass 
Memorial Medical Center, University 
of Massachusetts Medical School, 
worcester, MA, USA; 2Centocor 
Research and Development, inc., 
Malvern, PA, USA; 3University of 
Pennsylvania School of Medicine, 
Philadelphia, PA, USA
Correspondence:  Jonathan Kay 
Rheumatology Center, UMass Memorial 
Medical Center, Memorial Campus,  
119 Belmont Street, worcester,  
MA 01605, USA 
Tel +1 508 334 6273 
Fax +1 508 334 6038 
Email jonathan.kay@umassmemorial.org 
Introduction: The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a 
significant advance in the management of rheumatoid arthritis (RA) and other chronic inflam-
matory diseases. Although three TNF-α inhibitors have been approved for the treatment of 
RA by the US Food and Drug Administration (FDA) and the European Medicinal Products 
Evaluation Agency (EMEA), not all patients achieve a satisfactory clinical improvement with 
these therapeutic agents. The mode of administration of these medications is inconvenient for 
some patients.
Aims: Golimumab is a novel anti-TNF-α monoclonal antibody that is in clinical development for 
the treatment of RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), either as a first-
line biologic therapy or an alternative after other TNF-α inhibitors have been discontinued. This 
review summarizes the development of, and clinical evidence achieved with, golimumab.
Evidence review: Golimumab has demonstrated significant efficacy in randomized, double-
blind, placebo-controlled trials when administered subcutaneously once every four weeks. 
It has been generally well tolerated in clinical trials and demonstrates a safety profile comparable 
with currently available TNF-α inhibitors.
Outcomes summary: Golimumab has been confirmed to be an effective treatment for 
patients with RA, PsA, and AS in phase III clinical trials as evaluated by traditional measures of 
disease activity, such as signs and symptoms, as well as measures of physical function, patient 
reported outcomes, and health economic measures. The efficacy and safety profile of golimumab 
in RA, PsA, and AS appears to be similar to other anti-TNF agents. However, golimumab has 
the potential advantage of once monthly subcutaneous administration and the possibility of both 
subcutaneous and intravenous administration.
Keywords: golimumab, TNF-α inhibitors, rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis
Core evidence outcomes summary for golimumab
Outcome measure Evidence Implications
Patient-oriented evidence
Quality of life Substantial 
evidence
Golimumab improves functioning and quality 
of life in patients with PsA
Tolerability Clear 
evidence
Golimumab is well tolerated
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Introduction
Rheumatoid arthritis (RA) is a chronic and progressive 
systemic inflammatory disease characterized by chronic 
synovial inflammation that results in cartilage damage, 
progressive bone erosion, and functional decline. The 
prevalence of RA ranges from 0.5% to 1.0% and it occurs 
twice as often in women as in men.1 Psoriatic arthritis (PsA) is 
a spondyloarthropathy occurring in patients with chronic skin 
inflammation that is characterized by both chronic synovial 
and enthesial inflammation. Although the exact prevalence of 
PsA is unknown, it is estimated to be between 0.3% and 1.0%.2 
Ankylosing spondylitis (AS) is a spondyloarthropathy 
characterized by enthesial and axial skeletal inflammation 
that results in syndesmophyte formation with spinal fusion 
and also in progressive functional decline. The prevalence of 
AS ranges from 0.03% to 0.9% among white Europeans and 
East Asians and is lower among African Americans.1
Early and aggressive therapy that controls inflammation 
can drastically reduce or even stop the progression of 
joint erosion and, thus, optimize the functional ability and 
quality of life of patients with inflammatory polyarthritis or 
spondyloarthropathy.3–5 Significant progress in elucidating 
the pathophysiology of RA and other chronic inflammatory 
diseases has led to the identification of tumor necrosis factor-α 
(TNF-α) as a pivotal inflammatory mediator.6 The subsequent 
development of TNF-α inhibitors has proven to be a major 
advance in the treatment of RA, PsA, AS, and other chronic 
inflammatory diseases. Three TNF-α inhibitors are currently 
approved by the US Food and Drug Administration (FDA) 
for the treatment of RA, PsA, and AS: etanercept (Enbrel®), 
infliximab (Remicade®), and adalimumab (Humira®). 
Etanercept is a soluble dimeric p75 TNF-α receptor/Fc fusion 
construct,7 and was the first TNF-α inhibitor approved for the 
treatment of RA. Infliximab is a chimeric mouse/human anti-
TNF-α monoclonal antibody (mAb),8 and adalimumab is a 
humanized anti-TNF-α mAb.9 As a class, TNF-α antagonists 
have been proven to control the signs and symptoms of 
RA and to inhibit joint destruction. In addition, TNF-α 
antagonists control the signs and symptoms of PsA and AS 
and markedly improve activity of skin lesions in psoriasis. 
Adalimumab and infliximab have been approved for the 
treatment of inflammatory bowel diseases as well.10
Although many patients derive significant benefit from 
TNF-α inhibitors, there remains a population of patients 
who do not achieve a satisfactory clinical response with 
the currently available agents. Despite a limited amount 
of empiric evidence, clinical experience has shown that 
patients often respond to a second TNF-α inhibitor when they 
experience lack of efficacy or waning of response to the first 
one.11,12 Thus, the responses of individual patients to TNF-α 
a inhibitors are not homogeneous. Two additional TNF-α 
inhibitors are currently being developed: certolizumab pegol 
is a pegylated Fab-fragment of an anti-TNF-α antibody, and 
golimumab (GLM) is a human anti-TNF-α mAb. Thus, these 
new TNF-α inhibitors will provide additional therapeutic 
options for patients who are not responding adequately to 
(Continued)
Outcome measure Evidence Implications
Disease-oriented evidence
ACR and EULAR criteria in 
MTX-naïve RA patients
Substantial 
evidence
Equivalent to MTX; modest additional benefit 
of adding golimumab to MTX, similar to other 
TNF-α antagonists
ACR and EULAR criteria in patients 
with RA despite MTX
Substantial 
evidence
Adding golimumab to MTX confers significant 
additional benefit
ACR and EULAR criteria in patients 
with RA despite previous TNF-α 
antagonist therapy
Substantial 
evidence
Adding golimumab to background therapy 
confers significant additional benefit
ACR criteria, PASi and MASES scores 
in patients with PsA
Substantial 
evidence
Adding golimumab to background therapy 
confers significant additional benefit
ASAS, BASDAi, and BASFi 
criteria in patients with AS
Substantial 
evidence
Adding golimumab to background therapy 
confers significant additional benefit
Economic evidence
Cost effectiveness No evidence
Abbreviations:   ACR, American College of Rheumatology;   AS, ankylosing spondylitis;   ASAS, asessment in ankylosing 
spondylitis; BASDAi, Bath Ankylosing Spondylitis Activity index; BASFi, Bath Ankylosing Spondylitis Functional 
index; EULAR, European League Against Rheumatism; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; 
MTX, methotrexate; PASi, Psoriasis Area and Severity index; PsA, psoriatic arthritis; RA, rheumatoid arthritis.Core Evidence 2009:4 161
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currently available anti-TNF agents. The currently available 
anti-TNF agents are administered either intravenously or 
subcutaneously. The subcutaneous agents are administered 
twice a week to every two weeks. GLM will provide the 
option of once a month SC administration, which might be 
more convenient for patients who are currently injecting 
themselves every two weeks to twice a week.
This review describes the development and molecular 
characterization of GLM, and the preclinical data and early 
clinical trial experience with this novel anti-TNF-α mAb 
in patients with RA, PsA, and AS.
Pharmacology and characterization 
of golimumab
Molecular characterization
GLM was developed as a fully human monoclonal antibody 
that could inhibit TNF-α. Human immunoglobulin (Ig) 
transgenic mice (Medarex, Princeton, NJ) were immunized 
with human TNF-α and the resulting antibody-secreting 
hybridoma clones were screened by immunoassay for 
human light and heavy chains that bound to human TNF-α. 
These antibodies were isolated and ranked by their ability to 
neutralize TNF-α using a cytotoxicity assay. The antibody 
GLM consistently demonstrated high bioactivity and was 
cloned, sequenced, and re-expressed in transfected myeloma 
cells.13,14 The amino acid sequences of the constant regions of 
both heavy and light chains of GLM are human and thus are 
identical to the corresponding constant regions of infliximab. 
However, in contrast to the murine-derived heavy and light 
chain variable regions of infliximab, the corresponding 
variable regions of GLM are also human.15
In preclinical studies, the affinity of GLM for soluble 
TNF-α was assessed by surface plasmon resonance and 
kinetic exclusion assay that measure absorption and 
equilibrium binding affinity, respectively; the affinity for 
transmembrane TNF-α was assessed by radioimmunoassay; 
and TNF-α neutralizing capacity was assessed using 
several in vitro bioassays. Thermal stability was assessed 
by differential scanning calorimetry. GLM demonstrated 
high affinity for both soluble (17 pM) and transmembrane 
TNF-α (1.4 pM) and completely neutralized TNF-α, but 
did not inhibit lymphotoxin or show evidence of self 
association. Thus, GLM is a stable, human IgG1k mAb that 
demonstrates high affinity and specificity for human TNF-α 
and can neutralize TNF-α bioactivity in vitro. In vivo 
bioactivity was assessed in murine models of arthritis 
and psoriasis. Notably, in a murine transgenic model 
of arthritis (Tg197 mouse that constitutively expresses 
human TNF-α and develops an inflammatory arthritis that 
resembles human RA) GLM treatment reduced disease 
activity.13,14,16
Formulation
GLM exhibits multiple glycoforms in solution and has 
predicted molecular masses ranging from 149,802 daltons to 
151,064 daltons. GLM is intended for both subcutaneous (SC) 
and intravenous (IV) administration. For SC administration, it 
is manufactured in prefilled syringes and auto-injectors. Each 
milliliter also contains 0.87 mg L-histidine and L-histidine 
hydrochloride, 41.0 mg sorbitol, 0.15 mg polysorbate 80, 
and water. The histidine buffer formulation and GLM 
concentration were chosen to minimize discomfort on 
injection, which had been reported by patients to whom larger 
volumes of other biologic agents dissolved in citrate buffer 
were administered.17,18
Pharmacokinetics
The pharmacokinetics of GLM have been assessed in patients 
with RA following a single IV infusion or repeated SC 
injections.15,19 Noncompartmental analysis, compartmental 
analysis, and population pharmacokinetics were determined 
in a phase I trial of IV GLM, in which patients were 
randomized to receive placebo or GLM 0.1, 0.3, 1, 3, 
6, or 10 mg/kg.15 GLM was generally well tolerated in this 
trial and its pharmacokinetics appeared to be linear over the 
dose range evaluated.
In a phase II trial of 50 or 100 mg GLM administered 
subcutaneously, median trough GLM concentrations 
generally increased as the doses increased; however, 
there was large variability between patients. Serum GLM 
concentrations generally attained steady state by week 12 
for all dosage groups.20
Population pharmacokinetics were also assessed in 
phase III trials for patients with RA.19 For this analysis, 
a one-compartment pharmacokinetics model with first-
order adsorption and elimination was chosen to describe the 
observed concentration-versus-time data. Of all covariates 
tested, weight, concomitant use of methotrexate (MTX), 
antibody-to-GLM status, and baseline C-reactive protein 
(CRP) were identified as significant covariates for the 
apparent clearance of GLM, and weight was a significant 
covariate for volume of distribution.19 Serum golimumab 
concentrations were lower in patients who were not taking 
MTX, had antibodies to golimumab, were heavier, and had 
higher serum levels of CRP.Core Evidence 2009:4 162
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Clinical development of golimumab
Preclinical and phase I testing of GLM revealed no 
significant safety issues. There were no substantial 
differences between patients who received placebo and 
those who received GLM in incidence of infections, infusion 
reactions, hematology, clinical chemistry, vital signs, or 
electrocardiogram measurements in phase I testing.15 The 
clinical development program for GLM has so far included 
one phase II trial and four phase III trials in patients with RA, 
one phase III trial in patients with PsA, and one phase III 
trial in patients with AS.
Phase ii clinical trial
A 52-week, double-blind, placebo-controlled, phase II 
dose-ranging study of GLM was conducted in patients with 
active RA despite MTX therapy.20 Patients continued to 
receive stable doses of MTX and were randomly assigned 
to each of five treatment groups in approximately equal 
proportions: placebo, 50 mg GLM every four weeks, 
50 mg GLM every two weeks, 100 mg GLM every four 
weeks, or 100 mg GLM every two weeks. All patients 
continued to receive stable doses of MTX throughout the 
study (at least 10 mg/week). Study drug or placebo was 
administered by SC injection every two weeks through 
week 20. Patients who had been receiving placebo, in 
addition to MTX, during the first 20 weeks of the study 
were switched to receive infliximab (3 mg/kg) + MTX 
therapy in an unblinded manner at week 20 and thereafter. 
The primary endpoint was the proportion of patients in the 
combined GLM + MTX groups and also in at least one of 
the individual GLM + MTX dose groups that achieved at 
least 20% improvement in RA disease activity according 
to American College of Rheumatology response criteria 
(ACR20) at week 16. Secondary endpoints included ACR50 
and ACR70 responses at week 16; improvement in ACR20, 
ACR50, and ACR70 responses over time; improvement in 
numeric index of ACR response (ACR-N); improvement 
in Disease Activity Score using 28 joints (DAS28); and 
improvement in Health Assessment Questionnaire (HAQ) 
disability scores. At week 16, 61% of the patients in the 
combined GLM + MTX groups and 79% of the patients in 
the 100 mg GLM every two weeks + MTX group achieved 
an ACR20 response, compared with 37% of the patients 
receiving placebo + MTX (P = 0.010), thus achieving the 
primary endpoint.20 The ACR20, ACR50, and ACR70 
responses were maintained through week 52 for all doses 
(Figure 1). Efficacy was also demonstrated by each of the 
secondary endpoints.20
Selection of golimumab dose for the phase iii program
The 52-week, double-blind, placebo-controlled, phase II 
dose-ranging study of GLM was designed to assess the effect 
of fixed doses, 50 mg or 100 mg administered every two or 
four weeks. This study was powered to detect a significant 
effect of the combined golimumab arms compared with 
placebo; it was too small, with 35 subjects randomized 
to each arm, to detect treatment differences between the 
individual golimumab dose cohorts. A significantly greater 
proportion of subjects achieved an ACR20 response in 
the combined golimumab arms than in the placebo arm 
(P = 0.010). In addition, a significantly greater proportion 
of subjects receiving golimumab 100 mg every two weeks 
achieved an ACR20 response compared with those receiving 
placebo (P  0.001). However, all of the golimumab 
dose regimens showed numerically higher proportions of 
subjects achieving an ACR 20 response compared with 
placebo, with the 50 mg every four weeks arm approaching 
significance (P = 0.056). Among the patients taking each of 
the golimumab dose regimens, the proportion achieving an 
ACR50 response was significantly greater than among those 
receiving placebo, with the most robust response observed 
among those receiving golimumab 50 mg every four weeks 
(40%; P  0.001). Because of the small size of this phase II 
study, no difference in efficacy could be distinguished among 
the four arms studied. Although no difference was observed 
in the safety profile among the four dose arms, minimal 
exposure to drug is desirable. Thus, the dosages of 50 mg 
and 100 mg every four weeks were chosen for further evalu-
ation in the phase III program, since these were the lowest 
potentially effective golimumab doses and were considered to 
provide the most convenient dosing regimen for patients.
Phase iii clinical trials
GLM is being evaluated for the treatment of RA, PsA, and 
AS in several phase III trials: three trials in patients with RA 
treated with SC GLM, one trial in patients with RA treated 
with IV GLM, one trial in patients with PsA treated with 
SC GLM, and one trial in patients with AS treated with SC 
GLM. This review will focus on the five phase III trials of SC 
GLM for which 24-week data from the RA and AS trials21–25 
and 52-week data from the PsA trial26 were presented at 
the 2008 European League Against Rheumatism (EULAR) 
Annual Scientific Meeting (Table 1). Each of the studies 
was designed to include endpoints that measure signs and 
symptoms of disease, functional disability, radiographic 
progression, and health-related outcomes. Thus far, GLM has 
demonstrated efficacy consistent with that of the currently Core Evidence 2009:4 163
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Figure 1 Efficacy was maintained through 52 weeks in patients with active rheumatoid arthritis despite prior treatment with methotrexate. Percentage of patients meeting 
the American College of Rheumatology 20% improvement (ACR20) criteria (A), 50% improvement (ACR50) criteria (B), and 70% improvement (ACR70) criteria (C) through 
week 52. Copyright © 2008, American College of Rheumatology. Reprinted with permission from Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active 
rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.  Arthritis Rheum. 2008;58(4):964–975.Core Evidence 2009:4 164
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available TNF-α antagonists for all standard endpoints 
assessed. Additional endpoints were included in these trials 
to assess prospectively the effects of GLM on the long-term 
consequences of chronic inflammation and on patient quality 
of life.
Rheumatoid arthritis
Three phase III trials of SC administration of GLM have 
been conducted in three different subgroups of patients 
with RA. The GO-BEFORE trial was designed to assess the 
efficacy and safety of GLM administered every four weeks 
as monotherapy or in combination with MTX in patients 
with active RA who had not been previously treated with 
MTX (MTX-naïve). In this multicenter, double-blind, 
placebo-controlled trial, 637 patients were randomized 
to one of four treatment arms (Table 1). Among these 
patients, the median duration of disease ranged from 
1.0 to 1.8 years. The co-primary endpoints of the study 
were the proportion of patients who achieved ACR50 at 
week 24 and the change from baseline in van der Heijde 
Sharp (vdHS) score at week 52. To account for multiple 
comparisons, the prespecified hierarchical statistical testing 
was conducted for primary and major secondary endpoints. 
The combined GLM (50 mg and 100 mg ) + MTX group 
was compared first with MTX alone and, if significant at 
P = 0.05 level, a pairwise comparison between GLM 50 mg + 
MTX and GLM 100 mg + MTX was performed. If this test 
was positive, the noninferiority comparison between GLM 
100 mg alone and MTX alone would be performed.
By intent-to-treat (ITT) analysis, the primary endpoint 
of a greater proportion of patients in GLM (50 mg and 
100 mg) + MTX groups compared with MTX alone 
group achieving an ACR50 response at week 24 was not 
achieved.22 Nonetheless, when a modified ITT (mITT) 
analysis was performed that excluded three patients who 
were randomized but discontinued study participation 
before receiving any study treatment, the primary endpoint 
was achieved.22 The statistical significance of this differ-
ence, however, was borderline in both the ITT and mITT 
analyses. In the mITT analysis the proportion of patients 
treated with GLM 50 mg + MTX achieving an ACR50 
response at week 24 was significantly greater than the 
proportion of those treated with MTX alone. GLM alone 
was noninferior to MTX alone. Although the additional 
benefit of adding GLM to MTX in this patient population 
was modest, it was similar to that which has been observed in 
previous studies of other TNF-α antagonists in patients with 
early RA who had not been previously treated with MTX, 
such as the ERA trial of etanercept,3 the PREMIER trial 
of adalimumab,4 and the ASPIRE trial of infliximab.27 GLM 
Table 1 Phase iii trial design for GLM administered subcutaneously
Trial name Populationc n Treatment armsa Primary endpoint
GO-BEFORE MTX-naive patients with  
active RAb
637 Placebo + MTX  
GLM 100 mg + Placebo  
GLM 50 mg + MTX  
GLM 100 mg + MTX
ACR50 wk 24  
vdHS wk 52
GO-FORwARD Patients with active RA  
despite MTX treatment
444 Placebo + MTX  
GLM 100 mg + Placebo  
GLM 50 mg + MTX  
GLM 100 mg + MTX
ACR20 wk 14  
HAQ wk 24
GO-AFTER Patients with active RA  
despite previous treatment  
with TNF-α inhibitor(s)
461 Placebo  
GLM 50 mg  
GLM 100 mg
ACR20 wk 14
GO-REvEAL Adult PsA patients with skin  
and nail disease
405 Placebo  
GLM 50 mg  
GLM 100 mg
ACR20 wk 14
GO-RAiSE Adult patients with active ASd 356 Placebo  
GLM 50 mg  
GLM 100 mg
ASAS 20 wk 14
Notes: aAll GLM treatments were administered once every four weeks, and MTX treatment once every week. bActive rheumatoid arthritis; 4 tender joint count and 4 
swollen joint count. cPatients continued to receive MTX, sulfasalazine, or hydroxychloroquine if they were receiving them at baseline. dAccording to the modified New York 
criteria.30
Abbreviations:   ACR,   American College of Rheumatology;   AS, ankylosing spondylitis;   ASAS,   ASsessment in Ankylosing Spondylitis; GLM, golimumab; HAQ, Health Assessment 
Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumor necrosis factor; wk, week; vdHS, van der Heijde Sharp.Core Evidence 2009:4 165
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plus MTX demonstrated greater efficacy than placebo plus 
MTX for most of the secondary endpoints at week 24, which 
included DAS28 response (75.5% for both GLM 50 mg and 
100 mg + MTX versus 60.6% for placebo + MTX), DAS28 
remission (38.4% GLM 50 mg and 37.7% GLM 100 mg 
versus 28.1% placebo + MTX), and improvement in CRP 
levels (57% GLM 50 mg and 63% GLM 100 mg versus 25% 
placebo + MTX) in the prespecified ITT population. Further, 
GLM alone was noninferior to MTX alone in all measures 
of efficacy evaluated.22
Therefore, although this trial did not meet its prespecified 
primary endpoint, the efficacy of GLM in this MTX-naïve 
patient population with RA was supported by the outcome of 
most the other endpoints evaluated, and was similar to that 
which has been demonstrated for other TNF-α antagonists 
in MTX-naïve patients with early RA.3,4 The coprimary 
endpoint of inhibition of radiographic progression at week 52 
is yet to be reported for this trial.
The GO-FORWARD trial was designed to assess the 
efficacy and safety of GLM in patients with active RA 
despite MTX therapy. This multicenter double-blind, 
placebo-controlled trial of 444 patients included both GLM 
monotherapy and GLM + MTX combination treatment arms 
(Table 1). Patients could enter early escape if they did not 
achieve at least 20% improvement in both swollen and tender 
joint counts at week 16. Statistical analysis for this trial was 
performed as described above. The coprimary endpoints were 
the proportion of patients who achieved ACR20 at week 14 
and the improvement from baseline in HAQ at week 24. Both 
primary endpoints were met.24 Both 50 mg GLM + MTX 
and 100 mg GLM + MTX were comparable in efficacy and 
achieved statistical significance for all secondary endpoints 
at 24 weeks including ACR50, ACR70, DAS28 (using CRP) 
responders, and DAS28 (CRP) remission.24 Results from 
this trial confirm the efficacy of GLM in patients with active 
RA despite MTX therapy that was observed in the phase II 
trial,20 and demonstrate that 50 mg GLM or 100 mg GLM 
administered every four weeks in combination with MTX 
significantly reduces signs and symptoms and improves 
physical function in patients with RA.
The GO-AFTER trial was designed to assess the efficacy 
of an anti-TNF-α agent in patients with active RA despite 
previous treatment with other TNF-α antagonist(s). In this 
multicenter, double-blind, placebo-controlled prospective 
trial, 461 patients were randomized to three treatment arms 
(Table 1) and could enter early escape if they did not achieve 
at least 20% improvement in both swollen and tender joint 
counts at week 16. The primary endpoint was the proportion 
of patients achieving an ACR20 response at week 14 for the 
combined GLM groups based on the prespecified hierarchical 
statistical test procedure described above. All patients had 
been treated previously with at least one TNF-α inhibitor: 
115 patients (24.9%) had been treated with two TNF-α 
inhibitors, and 43 patients (9.3%) had previously received all 
three commercially available TNF-α inhibitors.25 Patients had 
discontinued prior TNF-α antagonist therapy because of lack 
of efficacy (58.4%), intolerance (16.5%), or “other reasons” 
(39.7%), most often financial. Among patients with active 
RA who received prior anti-TNF-α therapy and discontin-
ued for any reason, GLM significantly reduced signs and 
symptoms of  RA and improved physical function at week 24 
as assessed by ACR20, ACR50, and improvement in HAQ 
scores (P  0.001 for all measures for each GLM treatment 
arm compared individually with placebo).25 Among patients 
who had discontinued prior TNF-α antagonist therapy 
because of lack of efficacy, 35.7% and 42.7% of patients in 
the GLM 50 mg and 100 mg groups, respectively, achieved 
an ACR20 response at week 14 compared with 17.7% in 
the placebo group (P  0.001).25 GLM treatment similarly 
resulted in significant improvements in DAS28 response 
and remission. Serious adverse events and serious infec-
tions occurred at a lower rate among GLM-treated patients, 
but these randomized controlled trials were not powered to 
detect statistically significant differences in relatively rare 
adverse events.25
This study is the first double-blind, placebo-controlled 
prospective trial to demonstrate the efficacy of an anti-TNF-α 
agent in patients with active RA despite previous treatment 
with other TNF-α antagonist(s), and supports the use of 
GLM in patients who have experienced loss of efficacy, or 
are intolerant, to treatment with another TNF-α inhibitor.
Psoriatic arthritis
The GO-REVEAL trial was designed to assess the efficacy 
and safety of GLM in reducing the signs and symptoms of 
active PsA and associated skin and nail disease. In this mul-
ticenter, randomized, placebo-controlled trial, 405 patients 
received placebo, or GLM 50 or 100 mg (Table 1). The pri-
mary endpoint was the proportion of patients that achieved 
an ACR20 response at week 14 stratified by MTX use, 
which was permitted but not required. Additional endpoints 
included the Psoriasis Area and Severity Index (PASI) scores, 
improvement in enthesitis and dactylitis, and resolution of 
nail involvement.
After 52 weeks of treatment, GLM improved signs 
and symptoms of PsA significantly better than did placebo Core Evidence 2009:4 166
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(P  0.001; GLM 50 or 100 mg).23,26 Concomitant use of 
MTX did not affect efficacy. All comparisons between 
GLM 50 or 100 mg with placebo, including HAQ scores, 
ACR50, ACR70, DAS28 responders, and PASI scores 
were significant at week 24 (P  0.001 for all measures).26 
The effect of GLM on physical function and self-reported 
productivity of patients with PsA, as well as on time lost 
from work by caregivers of patients, was also assessed. 
Patients treated with GLM demonstrated significantly 
greater improvement from baseline in physical function, as 
measured by Short Form-36 (SF-36) physical component 
summary scores (PCS), SF-36 mental component summary 
scores (MCS), and HAQ scores, as well as in self-reported 
productivity and caregiver time lost from work at both weeks 
14 and 24, compared to those treated with placebo.28 Thus, 
GLM treatment not only significantly improved signs and 
symptoms of active PsA but also enhanced physical function 
and health-related quality of life.
Additional endpoints in the GLM PsA trial assessed 
the effects of GLM treatment on nail disease, dactylitis, 
and enthesitis, which are features of PsA that significantly 
affect patients but are not typically measured in clinical 
trials of drug therapies for PsA. The Nail Psoriasis Severity 
Index (NAPSI), which analyzes the single worst psoriasis-
affected nail, was used to evaluate nail involvement. The Nail 
Physician’s Global Assessment (NPGA) was used to evaluate 
all fingernails (scored from 1 to 5; 1 = absence of; 5 = very 
severe). Dactylitis was assessed in each digit of both hands 
and feet and enthesis tenderness was scored in 15 body sites 
using the PsA-modified (with plantar fascia added) Maastricht 
Ankylosing Spondylitis Enthesitis Score (MASES). When 
administered SC every four weeks, GLM 50 or 100 mg 
significantly improved psoriatic nail changes, enthesitis, 
and dactylitis.29 Taken together, these data demonstrate that 
GLM treatment of patients with PsA improves signs and 
symptoms of articular, cutaneous, and entheseal disease, as 
well as physical function and quality of life.
Ankylosing spondylitis
The GO-RAISE trial was designed to evaluate the efficacy 
of GLM in treating the signs and symptoms of active AS. 
In this multicenter, randomized, double-blind, placebo-
controlled study, 356 patients with definite AS based 
on the modified New York criteria,30 a Bath AS Disease 
Activity Index (BASDAI) score  4, and a back pain score 
of 4 were randomly assigned to receive SC injections of 
placebo or GLM 50 or 100 mg every four weeks (Table 1). 
Randomization was stratified by CRP level. The primary 
endpoint was the proportion of patients with at least a 20% 
improvement in the Assessment in AS working group 
(ASAS) criteria at week 14 and was achieved in the trial 
(59.4% and 60.0% GLM 50 mg and 100 mg , respectively, 
versus 21.8% placebo; P  0.001).21 Clinical benefit was 
observed as early as four weeks after GLM treatment, and 
efficacy was maintained through week 24. In addition, other 
than for change in the Bath AS Metrology Index (BASMI) 
scores, all secondary endpoints were achieved at week 14. 
These included ASAS40, ASAS5/6, ASAS partial remission, 
and the Bath AS Functional Index (BASFI).21
Data from this trial were used to assess a novel 
measure of health-related quality of life for patients with 
AS: the relationship between functionality, as measured 
by the BASFI, and improvements in sleep, as measured 
by the Jenkins Sleep Evaluation Questionnaire (JSEQ). 
Treatment with GLM resulted in significant (P  0.001) 
improvements in both BASFI and JSEQ at week 14 compared 
with placebo.31 Moreover, there was a positive correlation 
between change from baseline in BASFI and change from 
baseline in JSEQ at week 14 in the GLM-treated groups that 
was not observed in the placebo-treated group (r = 0.30, 
P = 0.0005 for GLM 50 mg ; r = 0.44, P  0.0001, for 
GLM 100 mg; versus r = 0.11, P = 0.34 for placebo).31–33 
Overall, GLM improved the signs and symptoms of AS, as 
well as physical function and sleep of patients with active 
AS, through 24 weeks of treatment.
Comorbidities of chronic 
inflammatory disease
Patients with chronic inflammatory diseases, such as RA, 
are at increased risk to develop comorbid conditions.34,35 The 
risks of developing coronary artery disease, insulin resis-
tance, anemia, infection, and malignancies – lymphoma in 
particular – are increased among patients with RA.34,35 A 2005 
Mayo Clinic study found that RA patients have a twofold 
increased risk of developing heart disease that is independent 
of traditional risk factors such as diabetes, alcohol abuse, 
elevated cholesterol, blood pressure, and body mass index.36,37 
The consequences of RA may lead to premature mortality; 
the mean life expectancy for patients with RA is reduced by 
between 5 to 10 years.38 Increasing evidence suggests that 
chronic inflammation contributes to the development of these 
long-term complications of RA.39
The effects of GLM therapy on markers of comorbidi-
ties of chronic inflammatory disease have been assessed 
prospectively in the phase III trials of GLM in RA, PsA, and 
AS (Tables 2, 3, and 4). Patients with anemia (according to Core Evidence 2009:4 167
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laboratory standards) at baseline were analyzed on entry into 
each of the five clinical trials of SC GLM (GO-BEFORE, 
GO-FORWARD, GO-AFTER, GO-RAISE, and GO-
REVEAL), and a subset of patients with anemia of chronic 
disease (anemic and ferritin level  60 ng/mL) was also 
analyzed.40 In the RA, PsA, and AS studies, 20%, 9%, and 
15% of patients respectively, had anemia at baseline. GLM 
treatment significantly improved anemia compared with 
placebo.40 Associations between the change in hemoglobin 
(Hb) levels and that in the SF-36 vitality scale or that in 
physical function, as measured using the HAQ disability 
index, were assessed through week 24. Hb increased 
significantly more in RA, AS, and PsA patients treated with 
GLM than in those treated with placebo, and a significantly 
greater number of GLM-treated patients achieved normal 
Hb levels. Significantly greater improvement in SF-36 
vitality scores was observed in patients treated with GLM, 
and the pooled analysis demonstrated a correlation between 
increases in Hb levels and improvement in SF-36 vitality 
scores (r = 0.23, P = 0.0071). Analysis of biomarkers for 
cardiovascular disease and insulin resistance is ongoing to 
determine whether GLM treatment might also reduce the 
likelihood of developing these comorbidities of chronic 
inflammation.
Safety
In clinical trials, the safety profile of GLM is comparable 
to those of other TNF-α inhibitors41 As a class, TNF-α 
Table 2 Results achieved with golimumab in patients with RA
Study and  
treatment groups (n)
Outcome (% of patients, level of significance vs placebo) 
  ACR20 ACR50 ACR70 EULAR response EULAR remission
GO-BEFORE
Placebo sc + MTX po (160) 49.4 29.4 15.6 61.3 11.3
GLM 100 mg sc + placebo po (159) 51.6 (noninferior) 32.7 (noninferior) 13.8 (noninferior) 67.3 (noninferior) 15.7 (noninferior)
GLM 50 mg sc + MTX po (159) 61.6 (P = 0.028) 40.3 (P = 0.042) 23.9 (P = 0.064) 73 (P = 0.027) 25.2 (P = 0.001)
GLM 100 mg sc + MTX po (159) 61.6 (P = 0.028) 36.5 (P = 0.177) 18.2 (P = 0.535) 76.7 (P = 0.003) 19.5 (P = 0.04)
GO-FORWARD
Placebo sc + MTX po (133) 27.8 13.5 5.3 42.1 6
GLM 100 mg sc + placebo po (133) 35.3 (P = 0.187) 19.5 (P = 0.187) 11.3 (P = 0.075) 51.9 (P = 0.11) 12 (P = 0.087)
GLM 50 mg sc + MTX po (89) 59.6 (P  0.001) 37.1 (P  0.001) 20.2 (P  0.001) 71.9 (P  0.001) 20.2 (P = 0.001)
GLM 100 mg sc + MTX po 59.6 (P  0.001) 32.6 (P  0.001) 14.6 (P = 0.017) 76.4 (P  0.001) 22.5 (P  0.001)
GO-AFTER
Placebo sc (155) 16.9 5.2 3.2 24.5 2.6
GLM 50 mg sc (153) 34 (P  0.001) 18.3 (P  0.001) 11.8 (P = 0.004) 46.4 (P  0.001) 10.5 (P  0.001)
GLM 100 mg sc (153) 43.8 (P  0.001) 20.3 (P  0.001) 10.5 (P  0.001) 60.8 (P  0.001) 15.7 (P  0.001)
Abbreviations: ACR20, 50, 70,   American College of Rheumatology 20%, 50%, and 70% improvement; EULAR, European League Against Rheumatism; GLM, golimumab; 
MTX, methotrexate; RA, rheumatoid arthritis; po, orally; sc, subcutaneously.
Table 3 Results achieved with golimumab in patients with PsA
Study and treatment  
groups (n)
Outcome (% of patients, level of significance vs placebo)
ACR20 ACR50 ACR70 PASI75 MASES index 
(for enthesitis)a
GO-REVEAL
Placebo sc (113) 12.4 3.2 0.9 1 11.7
GLM 50 mg sc (146) 52.1 (P  0.001) 32.2 (P  0.001) 18.5 (P  0.001) 56 (P  0.001) 60 (P  0.001)
GLM 100 mg sc (146) 61 37.7 21.2 66 66.7
Note: aMedian % improvement.
Abbreviations: ACR20, 50, 70,   American College of Rheumatology 20%, 50%, and 70% improvement; GLM, golimumab; MTX, methotrexate; MASES, Maastricht Ankylosing 
Spondylitis Enthesitis Score; PASi, Psoriasis Area and Severity index; PsA, psoriatic arthritis; po, orally; sc, subcutaneously.Core Evidence 2009:4 168
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Table 4 Results achieved with golimumab in patients with AS
Study and treatment 
groups (n)
Outcome (% of patients, level of significance vs placebo) 
ASAS20 ASAS40 ASAS partial  
remission
BASDAI (50%  
improvement)
BASFI score
GO-RAISE
Placebo sc (78) 23.1 15.4 5.1 14.7 0.03
GLM 50 mg sc (138) 55.8 (P  0.001) 43.5 (P  0.001) 23.2 (P  0.001) 50.8 (P  0.001) -1.64 (P  0.001)
GLM 100 mg sc (140) 65.7 (P  0.001) 54.3 (P  0.001) 21.9 (P  0.001) 47.8 (P  0.001) -1.60 (P  0.001)
Abbreviations: AS, ankylosing spondylitis; ASAS20, 40, ASessment in Ankylosing Spondylitis 20% and 40% improvement; BASDAi, Bath Ankylosing Spondylitis Activity index; 
BASFi, Bath Ankylosing Spondylitis Functional index; GLM, golimumab; MTX, methotrexate; po, orally; sc, subcutaneously.
inhibitors are associated with an increased risk of developing 
opportunistic infections and lymphoma, although the 
increased incidence of lymphoma observed in patients 
with RA treated with these drugs may not be higher than 
that which occurs in the overall population of patients with 
RA.42 Reactivation of latent tuberculosis (TB) can occur in 
patients treated with TNF-α inhibitors; therefore, routine TB 
screening and treatment of latent TB, if present, is recom-
mended before initiating treatment with any agent in this 
therapeutic class.12
In the GLM phase II trial, the most common adverse events 
reported were nausea, headache, injection site erythema, 
and worsening of RA disease activity. No cases of TB or 
lymphoma occurred, and the overall rate of infection in 
GLM-treated patients was comparable to that of the placebo 
group.20
GLM treatment was also well tolerated by patients 
enrolled in all five phase III trials of SC GLM, and reports 
of adverse events were consistent between the RA, AS, 
and PsA study populations. Serious adverse events were 
reported in 2.3% to 9.7% of patients among all treatment 
arms, and serious infections were reported in 0.7% to 5.6% 
of patients. One case of bone TB infection was reported in a 
patient receiving GLM 50 mg + MTX in the GO-BEFORE 
trial. Notably, injection site reactions were reported at lower 
frequencies (0 to 10.5%) than with the other SC TNF-α 
antagonists, etanercept and adalimumab, possibly because 
of the unique formulation of GLM with a histidine buffer 
in a small volume. Malignancies were reported in GO-
BEFORE (two patients treated with placebo + MTX, one 
patient treated with GLM 50 mg + MTX, one patient treated 
with GLM 100 mg + MTX); GO-FORWARD (one patient 
treated with placebo + MTX, one patient treated with GLM 
100 mg + MTX, one patient treated with GLM 100 mg 
monotherapy) and GO-REVEAL (three patients treated with 
GLM 100 mg).
Analyses for the detection of antibodies to GLM were 
performed with a bridging immunoassay in which GLM was 
used to capture and detect antibodies to GLM. Antibodies 
against GLM were detected in a small number of patients 
in all studies. Antibodies to GLM were detected in seven 
(6.5%) of the 107 GLM-treated patients (five patients 
in the GLM 50 mg dose groups and two patients in the 
GLM 100 mg dose groups) at week 48 of the phase II trial in 
patients with RA.20 None of the patients who were positive 
for antibodies to GLM experienced a severe injection site 
reaction or serious adverse event, and none discontinued 
study agent because of lack of efficacy.20 Rates of anti-GLM 
antibody detection reported for the phase III trials were 
similar to or less than those observed for other anti-TNF 
monoclonal antibodies in clinical trials and ranged from 
3.7% (GO-AFTER) to 4.6% (GO-REVEAL) of GLM-treated 
patients.25,26
Outcomes summary
GLM is a new human anti-TNF-α monoclonal antibody 
that blocks the action of TNF-α both in in vitro and animal 
disease models. GLM has been confirmed to be an effective 
treatment for patients with RA (including those naïve 
to MTX, those inadequately responsive to MTX, and those 
previously treated with a TNF inhibitor), AS, and PsA in 
phase III clinical trials that have included traditional measures 
of disease activity and functional decline. The safety and 
tolerability of GLM are comparable to that of other TNF-α 
inhibitors. With SC administration every four weeks, GLM 
may effectively control disease activity with less frequent 
dosing than the other commercially available SC TNF-α 
antagonists. Structural progression after 52 weeks of GLM 
therapy has been measured, but the results are not yet 
available. The cost-effectiveness, efficacy, and toxicity of 
GLM relative to currently available agents and over the 
longer term remain to be established.Core Evidence 2009:4 169
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